MA38659A1 - Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate - Google Patents
Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamateInfo
- Publication number
- MA38659A1 MA38659A1 MA38659A MA38659A MA38659A1 MA 38659 A1 MA38659 A1 MA 38659A1 MA 38659 A MA38659 A MA 38659A MA 38659 A MA38659 A MA 38659A MA 38659 A1 MA38659 A1 MA 38659A1
- Authority
- MA
- Morocco
- Prior art keywords
- receptor antagonists
- glutamate receptor
- metabotropic glutamate
- hydrogen
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
La présente invention concerne des dérivés éthynyle de formule (i), dans laquelle y est n ou ch; r1 est un atome d'hydrogène, de fluor ou de chlore; et r2 est l'hydrogène ou un alkyle inférieur; ou un sel d'addition d'acide pharmaceutiquement acceptable desdits dérivés. On a découvert de façon surprenante que les composés de formule générale (i) sont des antagonistes du récepteur métabotrope du glutamate (modulateurs allostériques négatifs) pouvant être employés pour traiter l'anxiété et la douleur, la dépression, le syndrome de l'x fragile, les troubles du spectre autistique, la maladie de parkinson et le reflux gastro-œsophagien (gerd).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13175535 | 2013-07-08 | ||
PCT/EP2014/064272 WO2015004007A1 (fr) | 2013-07-08 | 2014-07-04 | Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38659A1 true MA38659A1 (fr) | 2016-02-29 |
MA38659B1 MA38659B1 (fr) | 2016-10-31 |
Family
ID=48745843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38659A MA38659B1 (fr) | 2013-07-08 | 2015-12-10 | Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate |
Country Status (28)
Country | Link |
---|---|
US (2) | US9682959B2 (fr) |
EP (1) | EP3019486B1 (fr) |
JP (1) | JP6116761B2 (fr) |
KR (1) | KR101767348B1 (fr) |
CN (1) | CN105358543B (fr) |
AR (1) | AR096824A1 (fr) |
AU (1) | AU2014289398B2 (fr) |
BR (1) | BR112015029724A2 (fr) |
CA (1) | CA2914282A1 (fr) |
CL (1) | CL2015003761A1 (fr) |
CR (1) | CR20150650A (fr) |
DK (1) | DK3019486T3 (fr) |
EA (1) | EA027882B1 (fr) |
ES (1) | ES2628206T3 (fr) |
HK (1) | HK1215573A1 (fr) |
HU (1) | HUE033270T2 (fr) |
IL (1) | IL242682B (fr) |
MA (1) | MA38659B1 (fr) |
MY (1) | MY181847A (fr) |
PE (1) | PE20160604A1 (fr) |
PH (1) | PH12015502692A1 (fr) |
PL (1) | PL3019486T3 (fr) |
SG (1) | SG11201510607RA (fr) |
SI (1) | SI3019486T1 (fr) |
TW (1) | TWI527808B (fr) |
UA (1) | UA116023C2 (fr) |
WO (1) | WO2015004007A1 (fr) |
ZA (1) | ZA201508410B (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107849006B (zh) | 2015-06-03 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 乙炔基衍生物 |
US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
HUE057202T2 (hu) | 2017-12-14 | 2022-04-28 | H Lundbeck As | Kombinációs kezelések 1H-pirazolo[4,3-b]piridinek alkalmazásával |
AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
US11535611B2 (en) | 2017-12-20 | 2022-12-27 | H. Lundbeck A/S | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN153523B (fr) * | 1980-06-02 | 1984-07-21 | American Cyanamid Co | |
FI90869C (fi) * | 1986-11-14 | 1994-04-11 | Tanabe Seiyaku Co | Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi |
TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
TWI292318B (en) | 2003-03-10 | 2008-01-11 | Hoffmann La Roche | Imidazol-4-yl-ethynyl-pyridine derivatives |
EP2380889B1 (fr) * | 2004-10-07 | 2013-06-26 | Merck Sharp & Dohme Corp. | Antagonistes MGLUR5 de thiazolyl et leurs procédés d'utilisation |
US8389536B2 (en) * | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
EP2702050B1 (fr) | 2011-04-26 | 2016-05-18 | F.Hoffmann-La Roche Ag | Dérivés de pyrazolidine-3-one |
HUE025031T2 (en) * | 2011-04-26 | 2016-02-29 | Hoffmann La Roche | Ethinyl derivatives as positive allosteric modulators of MGLUR5 |
UA110862C2 (uk) * | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
-
2014
- 2014-04-07 UA UAA201600580A patent/UA116023C2/uk unknown
- 2014-07-04 PL PL14739714T patent/PL3019486T3/pl unknown
- 2014-07-04 BR BR112015029724A patent/BR112015029724A2/pt not_active Application Discontinuation
- 2014-07-04 SI SI201430233A patent/SI3019486T1/sl unknown
- 2014-07-04 DK DK14739714.5T patent/DK3019486T3/en active
- 2014-07-04 JP JP2016524753A patent/JP6116761B2/ja active Active
- 2014-07-04 EA EA201690162A patent/EA027882B1/ru not_active IP Right Cessation
- 2014-07-04 EP EP14739714.5A patent/EP3019486B1/fr active Active
- 2014-07-04 SG SG11201510607RA patent/SG11201510607RA/en unknown
- 2014-07-04 WO PCT/EP2014/064272 patent/WO2015004007A1/fr active Application Filing
- 2014-07-04 TW TW103123204A patent/TWI527808B/zh not_active IP Right Cessation
- 2014-07-04 CN CN201480038739.XA patent/CN105358543B/zh active Active
- 2014-07-04 ES ES14739714.5T patent/ES2628206T3/es active Active
- 2014-07-04 CA CA2914282A patent/CA2914282A1/fr not_active Abandoned
- 2014-07-04 KR KR1020167000013A patent/KR101767348B1/ko active IP Right Grant
- 2014-07-04 HU HUE14739714A patent/HUE033270T2/en unknown
- 2014-07-04 AU AU2014289398A patent/AU2014289398B2/en not_active Ceased
- 2014-07-04 MY MYPI2015003036A patent/MY181847A/en unknown
- 2014-07-04 PE PE2015002663A patent/PE20160604A1/es not_active Application Discontinuation
- 2014-07-07 AR ARP140102508A patent/AR096824A1/es unknown
-
2015
- 2015-11-13 ZA ZA2015/08410A patent/ZA201508410B/en unknown
- 2015-11-19 IL IL242682A patent/IL242682B/en not_active IP Right Cessation
- 2015-12-02 PH PH12015502692A patent/PH12015502692A1/en unknown
- 2015-12-08 CR CR20150650A patent/CR20150650A/es unknown
- 2015-12-10 MA MA38659A patent/MA38659B1/fr unknown
- 2015-12-30 CL CL2015003761A patent/CL2015003761A1/es unknown
-
2016
- 2016-01-08 US US14/991,748 patent/US9682959B2/en active Active
- 2016-03-24 HK HK16103513.4A patent/HK1215573A1/zh unknown
-
2017
- 2017-04-17 US US15/489,295 patent/US9751856B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38659B1 (fr) | Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate | |
MA38012B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 | |
MA31865B1 (fr) | Dérivés isoxazolo-pyridine | |
TW200616620A (en) | Compounds for the treatment of inflammatory disorders | |
MA42339A1 (fr) | Modulateurs du récepteur farnésoïde x | |
TW200612911A (en) | Compounds for the treatment of inflammatory disorders | |
MA29335B1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
MA38217B1 (fr) | Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2 | |
MA38323A1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
MA30355B1 (fr) | Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3 | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
MA34609B1 (fr) | Composé de cyclopropane | |
MA49127B1 (fr) | Dérivés d'indole n-substitués | |
TW200630341A (en) | Quinoline as allosteric enhancers of the GABA-B receptors | |
MA39750A (fr) | Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2 | |
MA38011A1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5 | |
UA114008C2 (xx) | Похідні етинілу як модулятори активності рецептора mglur5 | |
MA37941B1 (fr) | Dérivés d'aryléthynyle | |
MA37895A1 (fr) | Dérivés d'aryléthynylpyrimidine substitués modulateurs allostériques du récepteur métabotrope 5 de glutamate, utiles pour le traitement, par ex. Schizophrénie, maladies cognitives, syndrome x fragile, autisme, psychose et obésité | |
MA42508B1 (fr) | Dérivés d'éthynyle | |
TN2009000205A1 (fr) | Analogues de pyrazoles | |
MA33386B1 (fr) | Derives d'imidazole en tant qu'antagonistes de mglur5 | |
MA49910B1 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins | |
MA39054B1 (fr) | Dérivés pyridyle bicycliques à anneaux fusionnés utilisés en tant qu'inhibiteurs de fgfr4 |